Trials / Completed
CompletedNCT00240617
Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks
A Randomized, Double-blind, Multi-center, Placebo-controlled, Cross-over Study to Determine the Consistency of Response for Trexima* (Sumatriptan 85mg/Naproxen Sodium 500mg) Administered During the Mild Pain Phase for the Acute Treatment of Multiple Migraine Attacks (*Treximet)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 623 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the consistency of response for Treximet (formerly known as Trexima) when treating four acute migraine attacks at the mild pain phase and within 1 hour of onset of head pain.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | sumatriptan succinate/naproxen sodium | comparator |
| DRUG | placebo | placebo to match |
Timeline
- Start date
- 2005-10-01
- Primary completion
- 2006-06-01
- Completion
- 2006-06-01
- First posted
- 2005-10-18
- Last updated
- 2016-10-26
Locations
52 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00240617. Inclusion in this directory is not an endorsement.